Roquefort Therapeutics PLC

ROQ

Company Profile

  • Business description

    Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

  • Contact

    85 Great Portland Street
    First Floor
    LondonW1W 7LT
    GBR

    T: +44 2039188633

    https://www.roquefortplc.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    1

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries7,847.60205.10-2.55%
CAC 407,324.96274.02-3.61%
DAX 4020,863.64853.75-3.93%
Dow JONES (US)39,608.64937.29-2.31%
FTSE 1008,174.52300.22-3.54%
HKSE22,849.81352.72-1.52%
NASDAQ16,079.46471.14-2.85%
Nikkei 22533,780.58955.35-2.75%
NZX 50 Index12,225.28113.29-0.92%
S&P 5005,269.51127.01-2.35%
S&P/ASX 2007,667.80191.90-2.44%
SSE Composite Index3,342.018.12-0.24%

Market Movers